Efficacy of Educational Intervention as Supporting Element in the Treatment of Functional Constipation in Children
Primary Purpose
Constipation - Functional
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Educational information
Sponsored by
About this trial
This is an interventional treatment trial for Constipation - Functional focused on measuring fluid intake, functional constipation, children, PEG, macrogol, educational intervention
Eligibility Criteria
Inclusion Criteria:
Children with functional constipation diagnosed based on Rome IV criteria
Exclusion Criteria:
- Children with organic causes of constipation; eg, anorectal malformations, or Hirschsprung's disease
- Children who fulfil the criteria of Irritable Bowel Syndrome
- Significant, unstabilised chronic health conditions requiring major drug adjustment during the last 3 months.
- Unintentional weight loss greater than or equal to 5% of their body weight within the last 3 months
- Recurrent or unexplained fevers
- History of abdominal surgery involving the luminal gastrointestinal tract, except appendectomy, or hernia repairs
- Concomitant use of drugs that are known to affect gastrointestinal motility
- Established diagnoses of autism spectrum disorders
- Mental retardation
- Children who are exclusively breastfed
- Non-retentive faecal incontinence
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Study Group
Control Group
Arm Description
Macrogol (PEG 3350, PEG 4000), standard dosage Educational intervention: Recommendation of adequate for age fluid intake plus standard information about non-pharmacological supporting treatment
Macrogol (PEG 3350, PEG 4000), standard dosage Standard educational information about non-pharmacological supporting treatment
Outcomes
Primary Outcome Measures
Number of Participants who no longer fulfill the Rome IV constipation criteria
Success of therapy defined as no longer fulfilling the Rome IV constipation criteria during the last week of intervention.
Secondary Outcome Measures
Average daily fluid intake (ml) before the beginning of the intervention and during the last week of intervention
Assessed by a 2-day food and fluid intake diary made by patient and/or caregiver at the beginning of the intervention and during the last week of intervention
Frequency (number per week) of bowel movements during the fourth and last weeks of intervention
One of the Rome IV constipation criteria
Frequency of fecal incontinence (number per week) during the fourth and last weeks of intervention
One of the Rome IV constipation criteria
Painful bowel movements (number per week) during the fourth and last weeks of intervention
One of the Rome IV constipation criteria
Stomachache and bloating (number of episodes per week) during the fourth and last weeks of intervention
Symptoms related to constipation
Macrogol dose (mg/kg/day) during the fourth and last weeks of intervention
Macrogol dose needed to achieve treatment success (no longer fulfilling the Rome IV constipation criteria).
Need for rescue laxative treatment during the intervention (number of cases)
In case of lack of bowel movements for three consecutive days, the macrogol dose will be augmented to 1-1.5g/kg/day until a bowel movement occurs.
Time (days) from the start of intervention needed to achieve treatment success.
Time needed to no longer fulfill the Rome IV constipation criteria
Adverse events during intervention (number and type of reported adverse events)
Any adverse events reported by the patient or caregiver
Full Information
NCT ID
NCT05191810
First Posted
December 29, 2021
Last Updated
March 2, 2022
Sponsor
Medical University of Warsaw
1. Study Identification
Unique Protocol Identification Number
NCT05191810
Brief Title
Efficacy of Educational Intervention as Supporting Element in the Treatment of Functional Constipation in Children
Official Title
Efficacy of Educational Intervention as Supporting Element in the Treatment of Functional Constipation in Children
Study Type
Interventional
2. Study Status
Record Verification Date
March 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
March 7, 2022 (Anticipated)
Primary Completion Date
December 30, 2024 (Anticipated)
Study Completion Date
December 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of Warsaw
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether educational intervention (recommendation of adequate fluid intake) is effective as an element supporting the treatment of functional constipation in children.
Detailed Description
Constipation is a common condition in children which affects around 10% of the paediatric population. In 95 % cases it is a functional disorder of the digestive tract, without any organic cause. Recommendations of lifestyle modifications accompanying pharmacological treatment of constipation are very popular among healthcare providers, although there is limited data concerning non-pharmacological treatment methods of this condition. Adequate for age fluid intake is now recommended for patients with constipation. Further research is needed to form stronger recommendations in the future. The purpose of this study is to determine whether educational intervention (recommendation of adequate fluid intake) is effective as an element supporting the treatment of functional constipation in children.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Constipation - Functional
Keywords
fluid intake, functional constipation, children, PEG, macrogol, educational intervention
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
110 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Study Group
Arm Type
Experimental
Arm Description
Macrogol (PEG 3350, PEG 4000), standard dosage Educational intervention: Recommendation of adequate for age fluid intake plus standard information about non-pharmacological supporting treatment
Arm Title
Control Group
Arm Type
No Intervention
Arm Description
Macrogol (PEG 3350, PEG 4000), standard dosage Standard educational information about non-pharmacological supporting treatment
Intervention Type
Behavioral
Intervention Name(s)
Educational information
Intervention Description
Educational information about non-pharmacological supporting treatment of functional constipation, involving recommendation of adequate for age fluid intake
Primary Outcome Measure Information:
Title
Number of Participants who no longer fulfill the Rome IV constipation criteria
Description
Success of therapy defined as no longer fulfilling the Rome IV constipation criteria during the last week of intervention.
Time Frame
last week of intervention
Secondary Outcome Measure Information:
Title
Average daily fluid intake (ml) before the beginning of the intervention and during the last week of intervention
Description
Assessed by a 2-day food and fluid intake diary made by patient and/or caregiver at the beginning of the intervention and during the last week of intervention
Time Frame
8 weeks
Title
Frequency (number per week) of bowel movements during the fourth and last weeks of intervention
Description
One of the Rome IV constipation criteria
Time Frame
8 weeks
Title
Frequency of fecal incontinence (number per week) during the fourth and last weeks of intervention
Description
One of the Rome IV constipation criteria
Time Frame
8 weeks
Title
Painful bowel movements (number per week) during the fourth and last weeks of intervention
Description
One of the Rome IV constipation criteria
Time Frame
8 weeks
Title
Stomachache and bloating (number of episodes per week) during the fourth and last weeks of intervention
Description
Symptoms related to constipation
Time Frame
8 weeks
Title
Macrogol dose (mg/kg/day) during the fourth and last weeks of intervention
Description
Macrogol dose needed to achieve treatment success (no longer fulfilling the Rome IV constipation criteria).
Time Frame
8 weeks
Title
Need for rescue laxative treatment during the intervention (number of cases)
Description
In case of lack of bowel movements for three consecutive days, the macrogol dose will be augmented to 1-1.5g/kg/day until a bowel movement occurs.
Time Frame
8 weeks
Title
Time (days) from the start of intervention needed to achieve treatment success.
Description
Time needed to no longer fulfill the Rome IV constipation criteria
Time Frame
8 weeks
Title
Adverse events during intervention (number and type of reported adverse events)
Description
Any adverse events reported by the patient or caregiver
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Children with functional constipation diagnosed based on Rome IV criteria
Exclusion Criteria:
Children with organic causes of constipation; eg, anorectal malformations, or Hirschsprung's disease
Children who fulfil the criteria of Irritable Bowel Syndrome
Significant, unstabilised chronic health conditions requiring major drug adjustment during the last 3 months.
Unintentional weight loss greater than or equal to 5% of their body weight within the last 3 months
Recurrent or unexplained fevers
History of abdominal surgery involving the luminal gastrointestinal tract, except appendectomy, or hernia repairs
Concomitant use of drugs that are known to affect gastrointestinal motility
Established diagnoses of autism spectrum disorders
Mental retardation
Children who are exclusively breastfed
Non-retentive faecal incontinence
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Piotr Dziechciarz, MD PhD
Phone
+48223179539
Email
piotr.dziechciarz@wum.edu.pl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Piotr Dziechciarz, MD PhD
Organizational Affiliation
Department of Pediatrics of the Medical University of Warsaw
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Plan to share data on request via e-mail
IPD Sharing Time Frame
1.01.2022-31.12.2024
IPD Sharing Access Criteria
we plan to share all individual patients data on every outcome measure on request from any other researcher after completion of the study
Citations:
PubMed Identifier
29656863
Citation
Koppen IJN, Vriesman MH, Saps M, Rajindrajith S, Shi X, van Etten-Jamaludin FS, Di Lorenzo C, Benninga MA, Tabbers MM. Prevalence of Functional Defecation Disorders in Children: A Systematic Review and Meta-Analysis. J Pediatr. 2018 Jul;198:121-130.e6. doi: 10.1016/j.jpeds.2018.02.029. Epub 2018 Apr 12.
Results Reference
background
PubMed Identifier
27144631
Citation
Benninga MA, Faure C, Hyman PE, St James Roberts I, Schechter NL, Nurko S. Childhood Functional Gastrointestinal Disorders: Neonate/Toddler. Gastroenterology. 2016 Feb 15:S0016-5085(16)00182-7. doi: 10.1053/j.gastro.2016.02.016. Online ahead of print.
Results Reference
background
PubMed Identifier
27144632
Citation
Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional Disorders: Children and Adolescents. Gastroenterology. 2016 Feb 15:S0016-5085(16)00181-5. doi: 10.1053/j.gastro.2016.02.015. Online ahead of print.
Results Reference
background
PubMed Identifier
24345831
Citation
Tabbers MM, DiLorenzo C, Berger MY, Faure C, Langendam MW, Nurko S, Staiano A, Vandenplas Y, Benninga MA; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition; North American Society for Pediatric Gastroenterology. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr. 2014 Feb;58(2):258-74. doi: 10.1097/MPG.0000000000000266.
Results Reference
background
PubMed Identifier
28450053
Citation
Boilesen SN, Tahan S, Dias FC, Melli LCFL, de Morais MB. Water and fluid intake in the prevention and treatment of functional constipation in children and adolescents: is there evidence? J Pediatr (Rio J). 2017 Jul-Aug;93(4):320-327. doi: 10.1016/j.jped.2017.01.005. Epub 2017 Apr 25.
Results Reference
background
PubMed Identifier
33737146
Citation
Santucci NR, Chogle A, Leiby A, Mascarenhas M, Borlack RE, Lee A, Perez M, Russell A, Yeh AM. Non-pharmacologic approach to pediatric constipation. Complement Ther Med. 2021 Jun;59:102711. doi: 10.1016/j.ctim.2021.102711. Epub 2021 Mar 15.
Results Reference
background
PubMed Identifier
29380480
Citation
Koppen IJN, Saps M, Lavigne JV, Nurko S, Taminiau JAJM, Di Lorenzo C, Benninga MA. Recommendations for pharmacological clinical trials in children with functional constipation: The Rome foundation pediatric subcommittee on clinical trials. Neurogastroenterol Motil. 2018 Apr;30(4):e13294. doi: 10.1111/nmo.13294. Epub 2018 Jan 30.
Results Reference
background
Learn more about this trial
Efficacy of Educational Intervention as Supporting Element in the Treatment of Functional Constipation in Children
We'll reach out to this number within 24 hrs